AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25652454 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05212384, administered intravenously once weekly at a maximum-tolerated dose (MTD) of 154 mg
Number of subjects: 77
Study 25653396 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott RealTime HCV RNA assay
Number of subjects: 663
Study 25653396 — intervention group
Group type: COMPARATOR
Intervention: High Pure System
Number of subjects: 663
Study 25653396 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott RealTime HCV RNA assay (<12 IU/ml)
Number of subjects: 663
Study 25653396 — intervention group
Group type: EXPERIMENTAL
Intervention: High Pure System or Abbott RealTime (<12 IU/ml)
Number of subjects: 663
Study 25653574 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg once daily
Number of subjects: 50
Study 25653574 — intervention group
Group type: COMPARATOR
Intervention: Fondaparinux 1.5 mg once daily
Number of subjects: 50
Study 25653574 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban 30 mg
Number of subjects: 50
Study 25653826 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine immediate-release (IR)
Number of subjects: 1761
Study 25653826 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine extended-release (XR)
Number of subjects: 1761
Study 25653826 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine XR
Number of subjects: 1761
Study 25653826 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine IR
Number of subjects: 1761
Study 25653826 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to XR
Number of subjects: 1761
Study 25653826 — intervention group
Group type: COMPARATOR
Intervention: Continuous IR
Number of subjects: 1761
Study 25654354 — intervention group
Group type: COMPARATOR
Intervention: Rifampin 10 mg/kg (Control)
Number of subjects: 75
Study 25654354 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 20 mg/kg (Experimental)
Number of subjects: 75
Study 25654354 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 25 mg/kg (Experimental)
Number of subjects: 75
Study 25654354 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 30 mg/kg (Experimental)
Number of subjects: 75
Study 25654354 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 35 mg/kg (Experimental)
Number of subjects: 75
Study 25654540 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulse oscillometry (IOS) parameters
Number of subjects: 100
Study 25654812 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) 60-mg single dose
Number of subjects: 36
Study 25655063 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline haemodynamic severity (mean pressure gradient - MPG)
Number of subjects: 149
Study 25655063 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anatomic severity (degree of aortic valve calcification - AVC)
Number of subjects: 149
Study 25655063 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between annualised haemodynamic and anatomic progression rates
Number of subjects: 149
Study 25655063 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MPG and AVC as independent determinants of AVC progression
Number of subjects: 149
Study 25655379 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab 5.5 mg/kg
Number of subjects: 9
Study 25655379 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab 11.0 mg/kg
Number of subjects: 9
Study 25655379 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab (both doses)
Number of subjects: 9
Study 25655456 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25655621 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeta
Number of subjects: 374
Study 25655621 — intervention group
Group type: COMPARATOR
Intervention: Individualized PN
Number of subjects: 374
Study 25656734 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptavalent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 497
Study 25656734 — intervention group
Group type: COMPARATOR
Intervention: Non-vaccinated patients
Number of subjects: 497
Study 25658479 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of urge to eat (appetite control)
Number of subjects: 41
Study 25658479 — intervention group
Group type: COMPARATOR
Intervention: Passive viewing of food pictures
Number of subjects: 41
Study 25658479 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined eating of foods
Number of subjects: 41
Study 25659285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg once daily) plus Ribavirin (1000 mg or 1200 mg twice daily for 24 weeks or 12 weeks for treatment-naive genotype-2 patients)
Number of subjects: 275
Study 25659285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus Ribavirin
Number of subjects: 275
Study 25659436 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with clinically relevant depressive symptoms (CRDS) defined by a BDI-score ≥18
Number of subjects: 2007
Study 25659436 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 2007
Study 25659436 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CRDS
Number of subjects: 2007
Study 25659436 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ischemic stroke or TIA (n = 1,832)
Number of subjects: 2007
Study 25659911 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg (hepatic study)
Number of subjects: 16
Study 25659911 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 200 mg (renal study)
Number of subjects: 16
Study 25659911 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (renal study)
Number of subjects: 16
Study 25659911 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (both studies)
Number of subjects: 16
Study 25660004 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition preparation program
Number of subjects: 10
Study 25661570 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual compression (MC) performed by paramedics
Number of subjects: 3503
Study 25661570 — intervention group
Group type: COMPARATOR
Intervention: Manual compression (MC) performed by physicians
Number of subjects: 3503
Study 25661570 — intervention group
Group type: COMPARATOR
Intervention: Vascular closure devices (VCDs)
Number of subjects: 3503
Study 25663351 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 177
Study 25663351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 25664185 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir 300/100 mg qd
Number of subjects: 44
Study 25664185 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir 400/100 mg qd
Number of subjects: 44
Study 25664404 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-injection with the autoinjector (50 mg subcutaneous golimumab once monthly for 6 months)
Number of subjects: 3280
Study 25664404 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-injection with the autoinjector
Number of subjects: 3280
Study 25664534 — intervention group
Group type: COMPARATOR
Intervention: Blue dye alone
Number of subjects: 689
Study 25664534 — intervention group
Group type: COMPARATOR
Intervention: Radiolabeled colloid
Number of subjects: 689
Study 25664534 — intervention group
Group type: COMPARATOR
Intervention: Dual mapping agents (radiolabeled colloid and blue dye)
Number of subjects: 689
Study 25664534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping technique (blue dye vs radiolabeled colloid +/- blue dye)
Number of subjects: 689
Study 25664534 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SLN identification
Number of subjects: 689
Study 25664604 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral octreotide capsules (OOCs) 40 mg/d, escalated to 60 mg/d and then 80 mg/d for 7 months
Number of subjects: 155
Study 25664604 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral octreotide capsules (OOCs)
Number of subjects: 155
Study 25664714 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic bioabsorbable anal fistula plug
Number of subjects: 93
Study 25664865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate Care Unit (IMCU) present
Number of subjects: 5834
Study 25664865 — intervention group
Group type: COMPARATOR
Intervention: No Intermediate Care Unit (IMCU)
Number of subjects: 5834
Study 25665007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin treatment with ACYP2 risk variant (rs1872328)
Number of subjects: 238
Study 25665007 — intervention group
Group type: COMPARATOR
Intervention: Control group of 68 similarly treated children
Number of subjects: 238
Study 25665464 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-743921 with G-CSF (9 mg/m² MTD)
Number of subjects: 68
Study 25665464 — intervention group
Group type: COMPARATOR
Intervention: SB-743921 without G-CSF (6 mg/m² MTD)
Number of subjects: 68
Study 25665799 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention after DR1
Number of subjects: 14
Study 25665799 — intervention group
Group type: COMPARATOR
Intervention: Contouring dummy run (DR1)
Number of subjects: 14
Study 25665816 — intervention group
Group type: COMPARATOR
Intervention: Type 1 diabetes with inadequate glycemic control (T1D-I)
Number of subjects: 18
Study 25665816 — intervention group
Group type: COMPARATOR
Intervention: Type 1 diabetes with adequate glycemic control (T1D-A)
Number of subjects: 18
Study 25666151 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg/day
Number of subjects: 18
Study 25666151 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 18
Study 25666192 — intervention group
Group type: EXPERIMENTAL
Intervention: HCC with a doubling time of ≤53 days (n=19)
Number of subjects: 132
Study 25666192 — intervention group
Group type: EXPERIMENTAL
Intervention: HCC with a doubling time of 54-82 days (n=20)
Number of subjects: 132
Study 25666192 — intervention group
Group type: EXPERIMENTAL
Intervention: HCC with a doubling time of 83-110 days (n=20)
Number of subjects: 132
Study 25666192 — intervention group
Group type: EXPERIMENTAL
Intervention: HCC with a doubling time of ≥111 days (n=19)
Number of subjects: 132
Study 25666192 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-gene transcriptomic hepatic signature
Number of subjects: 132
Study 25666343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical elastography measurement using HI-RTE imaging in the first trimester
Number of subjects: 72
Study 25666343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical elastography index threshold value ≤0.38
Number of subjects: 72
Study 25666343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length ≤36mm combined with elasticity index ≤0.38
Number of subjects: 72
Study 25666356 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 14
Study 25667206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 1000 mg, two doses
Number of subjects: 30
Study 25667206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 30
Study 25667274 — intervention group
Group type: EXPERIMENTAL
Intervention: erlotinib for EGFR mutations
Number of subjects: 647
Study 25667274 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib for KRAS, NRAS, HRAS, or BRAF mutations
Number of subjects: 647
Study 25667274 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care therapies or biomarker-matched treatment groups
Number of subjects: 647
Study 25667274 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 647
Study 25667281 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-Guided Radiation Therapy (IGRT)
Number of subjects: 79
Study 25667281 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiation therapy without IGRT (from CAN-NCIC-SR2 trial)
Number of subjects: 79
Study 25667295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg
Number of subjects: 1861
Study 25667295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 1861
Study 25667295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (combined data from expanded access program)
Number of subjects: 1861
Study 25667973 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16
Number of subjects: 40901
Study 25667973 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV31
Number of subjects: 40901
Study 25667973 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV52
Number of subjects: 40901
Study 25667973 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV18
Number of subjects: 40901
Study 25667973 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 and HPV18
Number of subjects: 40901
Study 25668820 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable antiretroviral therapy
Number of subjects: 147
Study 25669310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary cysteine intake (mean, 635 mg/d)
Number of subjects: 34250
Study 25669310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of other amino acids
Number of subjects: 34250
Study 25669662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilaralisib 400 mg plus erlotinib 150 mg
Number of subjects: 35
Study 25669746 — intervention group
Group type: EXPERIMENTAL
Intervention: bapineuzumab treatment
Number of subjects: 262
Study 25669746 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 262
Study 25669746 — intervention group
Group type: EXPERIMENTAL
Intervention: antithrombotic agents
Number of subjects: 262
Study 25669829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib and vorinostat
Number of subjects: 78
Study 25670018 — intervention group
Group type: EXPERIMENTAL
Intervention: [(99m)Tc]Tilmanocept (50 µg, radiolabeled with either 0.5 mCi same day or 2.0 mCi next day)
Number of subjects: 101
Study 25670018 — intervention group
Group type: EXPERIMENTAL
Intervention: [(99m)Tc]Tilmanocept
Number of subjects: 101
Study 25670231 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (NT pro-BNP)
Number of subjects: 635
Study 25670231 — intervention group
Group type: EXPERIMENTAL
Intervention: high-sensitivity CRP (hsCRP)
Number of subjects: 635
Study 25670231 — intervention group
Group type: EXPERIMENTAL
Intervention: cystatin C (CysC)
Number of subjects: 635
Study 25670231 — intervention group
Group type: EXPERIMENTAL
Intervention: myeloperoxidase (MPO)
Number of subjects: 635
Study 25670231 — intervention group
Group type: EXPERIMENTAL
Intervention: high-sensitivity troponin I (hsTnI)
Number of subjects: 635
Study 25670231 — intervention group
Group type: EXPERIMENTAL
Intervention: von Willebrand factor (VWF)
Number of subjects: 635
Study 25670231 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score
Number of subjects: 635
Study 25670894 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 100
Study 25670894 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking controls
Number of subjects: 100
Study 25670894 — intervention group
Group type: COMPARATOR
Intervention: Current or ex-smoking controls
Number of subjects: 100
Study 25670896 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 0
Study 25670896 — intervention group
Group type: COMPARATOR
Intervention: Formoterol
Number of subjects: 0
Study 25670896 — intervention group
Group type: COMPARATOR
Intervention: As-needed short-acting β2-agonist (salbutamol)
Number of subjects: 0
Study 25671113 — intervention group
Group type: EXPERIMENTAL
Intervention: School garden intervention
Number of subjects: 12
Study 25671113 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 12
Study 25671576 — intervention group
Group type: EXPERIMENTAL
Intervention: PLIÉ
Number of subjects: 12
Study 25671576 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 12
Study 25671593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phones and Internet for participant tracking
Number of subjects: 21
Study 25671593 — intervention group
Group type: EXPERIMENTAL
Intervention: Texting as a communication tool
Number of subjects: 21
Study 25671593 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet searches (Google, paid databases, etc.)
Number of subjects: 21
Study 25671593 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media for participant tracking
Number of subjects: 21
Study 25671593 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall use of technology for participant tracking
Number of subjects: 21
Study 25672429 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise training, performed 3 times per week for 3 months.
Number of subjects: 123
Study 25672429 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 123
Study 25672894 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide for 1 year
Number of subjects: 0
Study 25672894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25672894 — intervention group
Group type: COMPARATOR
Intervention: Inhaled budesonide and Placebo
Number of subjects: 0
Study 25672916 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib (50, 80, and 100 mg/day) plus carboplatin AUC 5 and paclitaxel 175 mg/m(2) on day 1 of a 21-day cycle with pegfilgrastim support (Group 1)
Number of subjects: 30
Study 25672916 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib (50, 80, and 100 mg/day) plus carboplatin AUC 5 and paclitaxel 80 mg/m(2) on days 1, 8, and 15 of a 28-day cycle without growth factor support (Group 2)
Number of subjects: 30
Study 25672916 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib plus carboplatin + paclitaxel
Number of subjects: 30
Study 25674045 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer telephone smoking cessation counseling follow-up (2-4 times)
Number of subjects: 131
Study 25674045 — intervention group
Group type: COMPARATOR
Intervention: Volunteer telephone smoking cessation counseling follow-up (0-1 times)
Number of subjects: 131
Study 25674536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-vinorelbine
Number of subjects: 60
Study 25674536 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA and miRNA predictive signatures
Number of subjects: 60
Study 25674536 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA and miRNA prognostic signatures
Number of subjects: 60
Study 25674536 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of signatures
Number of subjects: 60
Study 25675863 — intervention group
Group type: EXPERIMENTAL
Intervention: BCR-ABL1+ ALLs with high CDK4 expression, phosphorylated pRb (p-pRb), and telomerase activity
Number of subjects: 123
Study 25675863 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced p16(INK4A) expression in BCR-ABL1+ ALLs
Number of subjects: 123
Study 25675863 — intervention group
Group type: COMPARATOR
Intervention: Philadelphia chromosome-negative/IKAROS-deleted (BCR-ABL1(-)/IKAROS(del)) cases
Number of subjects: 123
Study 25675863 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro analyses of normal stimulated lymphocytes
Number of subjects: 123
Study 25676000 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline statin use
Number of subjects: 10418
Study 25676000 — intervention group
Group type: COMPARATOR
Intervention: Aspirin use
Number of subjects: 10418
Study 25676427 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic research findings related to alopecia areata
Number of subjects: 0
Study 25676427 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapeutic strategies
Number of subjects: 0
Study 25677599 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up and Go test
Number of subjects: 298
Study 25677599 — intervention group
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale
Number of subjects: 298
Study 25677599 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed
Number of subjects: 298
Study 25677599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task walking performance
Number of subjects: 298
Study 25677599 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up and Go times >12 s at 6 months
Number of subjects: 298
Study 25677668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept (1.25 mg, 0.05 mL intravitreal injection)
Number of subjects: 6
Study 25677851 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (detectable TnT ≥0.01 ng/mL and BNP >440 pg/mL)
Number of subjects: 267
Study 25677851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-risk group (either detectable TnT or high BNP)
Number of subjects: 267
Study 25677851 — intervention group
Group type: COMPARATOR
Intervention: Low-risk group (nondetectable TnT and low BNP)
Number of subjects: 267
Study 25678046 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment (self-reported)
Number of subjects: 28
Study 25678046 — intervention group
Group type: COMPARATOR
Intervention: No cognitive impairment (control)
Number of subjects: 28
Study 25678143 — intervention group
Group type: EXPERIMENTAL
Intervention: cART
Number of subjects: 117
Study 25678281 — intervention group
Group type: EXPERIMENTAL
Intervention: FIREHAWK stent
Number of subjects: 1007
Study 25678411 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure of central venous catheter (CVC) removal in Group 1
Number of subjects: 248
Study 25678411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoalbuminaemia in Group 1
Number of subjects: 248
Study 25678411 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure of central venous catheter (CVC) removal in Group 2
Number of subjects: 248
Study 25678411 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation in Group 2
Number of subjects: 248
Study 25678411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoalbuminaemia in Group 2
Number of subjects: 248
Study 25678411 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropaenia in Group 2
Number of subjects: 248
Study 25678411 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender in Group 2
Number of subjects: 248
Study 25678831 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (PRM) nightly for 6 weeks
Number of subjects: 13
Study 25678831 — intervention group
Group type: COMPARATOR
Intervention: Placebo nightly for 6 weeks
Number of subjects: 13
Study 25679067 — intervention group
Group type: EXPERIMENTAL
Intervention: G + nP + T (gemcitabine + nab-paclitaxel + TH-302)
Number of subjects: 4
Study 25679067 — intervention group
Group type: COMPARATOR
Intervention: G + nP (gemcitabine + nab-paclitaxel)
Number of subjects: 4